Loss of HER2 Expression Post-Neoadjuvant Therapy in Breast Cancer
Neoadjuvant treatment (NAT), which is administered prior to surgery, has significantly changed the management of HER2-positive breast cancer. This approach not only increases the possibility of breast-conserving surgery but also provides insight into the disease response to therapy. However, an emerging concern is the loss of HER2 expression following neoadjuvant treatment, an event that could […]
Loss of HER2 Expression Post-Neoadjuvant Therapy in Breast Cancer Read More »